Call for Abstracts

You are invited to contribute a paper in any one of the themes outlined below. Abstracts must be submitted no later than the 30th June 2011.

Abstracts will be reviewed by the Abstract Grading Committee and may be accepted to any part of the meeting. The Scientific Program Committee reserves the right to assign accepted papers to any of the presentation formats. All presentation formats will form integral elements of the Scientific Program. An author may submit more than one abstract.

Follow the guidelines exactly as abstracts will not be retyped. Abstracts not complying with the guidelines may be withdrawn by the Scientific Program Committee.

Abstracts are invited on all aspects of Perfusion and related topics, research and clinical papers are welcome.

Papers will be presented as either free short (10 min) or long papers (15 min), or included as a focus point in a workshop.

In addition topics for inclusion in symposium and workshops are sought from participants at all times.

ABSTRACT DEADLINE: June 30, 2011

Abstract format instructions:

• See the example below and follow the format exactly. Title, authors and institutions must be included in the document you submit.
• Select arial font type size 10.
• Abstract word limit is 250. The word limit relates only to the text of the abstract and does not include title, authors and institutions.
• The complete abstract must be no more than 15cm wide and 12cm in length.
• Use single line spacing.
• TITLE should be in UPPER CASE, bold and at the top of the abstract.
• The name of the presenting author to be indicated by an underlining (Michael McDonald CCP (Aust), Robert A Baker CCP (Aust), Timothy Willcox CCP (Aust)). The authors’ names (Christian Middle initial Surname, highest degree) should be followed by the institution, city, country (Sentence case).
• Abbreviations may be used but must be spelt out in full at the first mention followed by the abbreviation in parentheses.
• Please proof read your abstract carefully.

SAMPLE ABSTRACT

CLOPIDOGREL AND BLEEDING AFTER CORONARY ARTERY BYPASS GRAFT SURGERY Jee-Yoong Leong MB BS, Vijit Cherian MCh, Robert A Baker PhD, John L Knight FRACS Cardiac and Thoracic Surgical Unit, Flinders Medical Centre, Bedford Park, South Australia, AUSTRALIA Background. Aspirin is the main antiplatelet medication used in patients with coronary artery disease, however there is growing evidence that the use of the more potent clopidogrel, on its own or in combination with aspirin, has superior outcomes. Clopidogrel has also been shown to increase the risk of bleeding after coronary artery bypass graft surgery, which is a significant cause of morbidity and mortality. We review the effect of the use of preoperative clopidogrel on bleeding-related complications after coronary artery bypass graft surgery in our institution. Methods. A retrospective analysis of all patients undergoing isolated coronary artery bypass graft surgery at the Flinders Medical Centre between July 2000 and June 2003. A comparison was made between patients who received preoperative clopidogrel with those who did not receive it. Also, a comparison was made between patients who were on clopidogrel only, aspirin only and neither medication. Results. A total of 919 patients were identified, of which 88 (9.6%) were on preoperative clopidogrel. Clopidogrel recipients had a higher volume of drain loss, were transfused more units of blood, and had longer intensive care unit and postoperative hospital stays than patients not exposed to clopidogrel. Conclusions. In the three year period studied, the data from our institution showed an increased risk of bleeding, blood transfusion and resource utilization in patients who were on clopidogrel before coronary artery bypass graft surgery.

Abstract Submissions

Electronic abstracts submission is preferred.
Email completed abstract (word document) to abstracts@perfusiondownunder.com .
Include in your email the presenter’s name, address, and telephone number.

Email Submission to TimW@adhb.govt.nz

or abstract may be mailed to:
Tim Willcox
Chief Perfusionist
Greenlane Perfusion
Auckland City Hospital
Private Bag 92024
Auckland Mail Centre
Auckland 1142
New Zealand

If abstract is mailed please include a copy on cd of the abstract in word document format. Include the presenter’s name, address, email address and telephone number.

Speaker Timeline
Deadline for receipt of abstracts
30th June 2011
Notification of acceptance
15th July 2011

Speaker Expenses
All presenters are required to pay their own registration, accommodation and travel expenses.